Spero Therapeutics (SPRO) Expected to Post Quarterly Sales of $620,000.00

Equities analysts expect that Spero Therapeutics (NASDAQ:SPRO) will report sales of $620,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Spero Therapeutics’ earnings, with the lowest sales estimate coming in at $430,000.00 and the highest estimate coming in at $800,000.00. The firm is scheduled to announce its next earnings results on Thursday, August 9th.

On average, analysts expect that Spero Therapeutics will report full-year sales of $5.39 million for the current fiscal year, with estimates ranging from $1.15 million to $10.38 million. For the next fiscal year, analysts anticipate that the business will post sales of $8.47 million per share, with estimates ranging from $1.15 million to $21.25 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Thursday, May 10th. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.46. The company had revenue of $1.15 million for the quarter, compared to analysts’ expectations of $0.20 million.

SPRO has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Spero Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Tuesday, January 30th. ValuEngine raised shares of Spero Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Cantor Fitzgerald initiated coverage on shares of Spero Therapeutics in a report on Thursday, February 8th. They set an “overweight” rating and a $27.00 price objective on the stock. Finally, Oppenheimer reissued a “buy” rating on shares of Spero Therapeutics in a report on Tuesday, March 20th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Spero Therapeutics currently has an average rating of “Buy” and a consensus price target of $25.00.

Several hedge funds and other institutional investors have recently made changes to their positions in SPRO. Dean Capital Investments Management LLC purchased a new stake in shares of Spero Therapeutics in the fourth quarter valued at about $118,000. Atlas Venture Associates IX LLC purchased a new stake in shares of Spero Therapeutics in the fourth quarter valued at about $16,179,000. California Public Employees Retirement System purchased a new stake in shares of Spero Therapeutics in the fourth quarter valued at about $294,000. BlackRock Inc. purchased a new stake in shares of Spero Therapeutics in the fourth quarter valued at about $2,830,000. Finally, Artal Group S.A. purchased a new stake in shares of Spero Therapeutics in the fourth quarter valued at about $4,113,000. 46.35% of the stock is currently owned by institutional investors.

SPRO stock opened at $12.10 on Friday. The stock has a market cap of $173.83 million and a P/E ratio of -0.68. Spero Therapeutics has a 52 week low of $9.66 and a 52 week high of $19.00.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply